Corindus Vascular Robotics Inc (NYSEAMERICAN:CVRS) Director Louis A. Cannon acquired 30,000 shares of the business’s stock in a transaction dated Wednesday, August 22nd. The shares were purchased at an average price of $0.99 per share, with a total value of $29,700.00. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website.

Shares of Corindus Vascular Robotics stock traded up $0.01 during mid-day trading on Friday, hitting $1.03. The stock had a trading volume of 497,528 shares, compared to its average volume of 1,050,401. Corindus Vascular Robotics Inc has a 12-month low of $0.66 and a 12-month high of $1.97.

Corindus Vascular Robotics (NYSEAMERICAN:CVRS) last posted its quarterly earnings results on Tuesday, August 7th. The medical equipment provider reported ($0.06) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.01). Corindus Vascular Robotics had a negative net margin of 323.84% and a negative return on equity of 110.93%. The firm had revenue of $1.67 million during the quarter, compared to analysts’ expectations of $3.00 million.

CVRS has been the subject of a number of research analyst reports. Zacks Investment Research upgraded Corindus Vascular Robotics from a “hold” rating to a “buy” rating and set a $1.25 price objective for the company in a research report on Tuesday, July 10th. LADENBURG THALM/SH SH began coverage on shares of Corindus Vascular Robotics in a research note on Monday, May 21st. They issued a “buy” rating and a $2.00 price target for the company. Finally, Stifel Nicolaus cut shares of Corindus Vascular Robotics from a “buy” rating to a “hold” rating and dropped their price target for the company from $3.00 to $1.00 in a research note on Wednesday, August 8th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have issued a buy rating to the company. The company presently has an average rating of “Hold” and an average price target of $1.50.

Several institutional investors have recently bought and sold shares of the company. BlackRock Inc. raised its holdings in shares of Corindus Vascular Robotics by 4.6% in the fourth quarter. BlackRock Inc. now owns 4,384,539 shares of the medical equipment provider’s stock valued at $4,428,000 after buying an additional 191,134 shares during the last quarter. Deutsche Bank AG raised its position in Corindus Vascular Robotics by 91.6% during the 4th quarter. Deutsche Bank AG now owns 250,179 shares of the medical equipment provider’s stock valued at $251,000 after purchasing an additional 119,611 shares during the last quarter. Millennium Management LLC bought a new position in Corindus Vascular Robotics during the 4th quarter valued at approximately $2,189,000. Migdal Insurance & Financial Holdings Ltd. bought a new position in Corindus Vascular Robotics during the 1st quarter valued at approximately $295,000. Finally, Bronfman E.L. Rothschild L.P. bought a new position in Corindus Vascular Robotics during the 1st quarter valued at approximately $161,000.

About Corindus Vascular Robotics

Corindus Vascular Robotics, Inc designs, manufactures, and sells robotic-assisted precision vascular systems for use in interventional vascular procedures in the United States and internationally. The company offers CorPath system, a medical device with robotic-assisted precision for radial, coronary, and peripheral procedures.

See Also: Should you buy a closed-end mutual fund?

Receive News & Ratings for Corindus Vascular Robotics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corindus Vascular Robotics and related companies with MarketBeat.com's FREE daily email newsletter.